Medpace Holdings, Inc. last reported quarterly results on Oct 21, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $716.0 million (+8.5% year over year) and diluted EPS of $4.84. It usually reports 21–40 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 8, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Feb 9, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 21–40 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 21, 2026
21 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
716
+8.5%
|
137
+23.7%
|
4.84
+25.4%
|
|
Jul 22, 2026
22 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
707
+17.2%
|
121
+34.5%
|
4.25
+37.1%
|
|
Apr 22, 2026
22 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
707
+26.5%
|
124
+8.1%
|
4.28
+16.6%
|
|
Feb 9, 2026
40 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
708
+32.0%
|
135
+15.5%
|
4.66
+27.0%
|
|
Oct 22, 2025
22 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
660
+23.7%
|
111
+15.3%
|
3.86
+28.2%
|
|
Jul 21, 2025
21 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
603
+14.2%
|
90
+2.2%
|
3.10
+12.7%
|
|
Apr 21, 2025
21 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
559
+9.3%
|
115
+11.7%
|
3.67
+14.7%
|
|
Feb 10, 2025
41 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
537
+7.7%
|
117
+49.5%
|
3.67
+49.4%
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MEDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cincinnati, OH
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1668397
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.